Certified by Founder
Lodge
Alveus Therapeutics Inc
start up
United States
- Philadelphia, Pennsylvania
- 09/01/2026
- Series A
- $160,000,000
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
- Industry Biotechnology Research
- Website https://alveustx.com/
- LinkedIn https://www.linkedin.com/company/alveus-therapeutics/
Bubble Robotics | $5,000,000 | (Apr 23, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)
Mosaic(US) | $18,000,000 | (Apr 23, 2026)
Omeza | $8,500,000 | (Apr 23, 2026)
Calibre | $3,300,000 | (Apr 23, 2026)
Nox Mobility | $2,341,030 | (Apr 23, 2026)
BuildForever | $9,500,000 | (Apr 23, 2026)
10x Science (YC W26) | $4,800,000 | (Apr 23, 2026)
Schematic | $6,500,000 | (Apr 23, 2026)
Crewline | $7,100,000 | (Apr 23, 2026)
Monk | $25,000,000 | (Apr 22, 2026)
NeoCognition | $40,000,000 | (Apr 22, 2026)